Bremelanotide acetate is under clinical development by Cosette Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bremelanotide acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bremelanotide acetate overview
Bremelanotide acetate (Vyleesi) is belongs to class of organic compounds known as oligopeptides. It is formulated as solution for subcutaneous route of administration. Vyleesi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), characterized by low sexual desire that causes marked distress or interpersonal difficulty.
Bremelanotide acetate is under development for diabetic kidney disease, premenopausal women with hypoactive sexual desire disorder, impaired female sexual desire, obesity. It was under development as a intranasal formulation for the treatment of female sexual dysfunction and erectile dysfunction. It is a self administered subcutaneous auto-injector. The drug candidate is a synthetic peptide analog of alpha-melanocyte stimulating hormone (a-MSH) which acts by targeting melanocortin 4 receptor. It is developed based on MIDAS (Metal Ion-induced Distinctive Array of Structures) drug discovery platform.
Cosette Pharmaceuticals overview
Cosette Pharmaceuticals (Cosette) is a diversified pharmaceutical company. It specializes in branded, generic, and over the counter (OTC) pharmaceuticals in women’s health, cardiology, and dermatology medicine portfolio. The company develops products in dosage forms such as topical creams, ointments, oral liquids and solutions, lotions, and suppositories. Cosette also offers contract development and manufacturing services which include product development, technical transfer, scale-up, manufacturing, packaging, serialization, stability programs, and testing services. The company operates corporate and manufacturing facilities in New Jersey and North Carolina, the US. It was funded by Avista Capital Partners. Cosette is headquartered in Somerset, New Jersey, the US.
For a complete picture of Bremelanotide acetate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
